CurrentRheuma — Gout & crystal arthritis

The impact of HFE genotypes and iron loading on joint disease: evidence for HFE-associated arthropathy without genetic haemochromatosis

2026-11-05T13:24:18.717Z

Research article · Ann Rheum Dis, 2026.

Effects of a Smartphone‐Enabled, Physician‐Supervised Treat‐to‐Target Model for Gout Management: A 12‐Month Randomized Controlled Trial

2026-11-05T13:10:58.883Z

Randomized controlled trial · Arthritis Rheumatol, 2026.

Association between serum free fatty acid levels and tophus in patients with gout: a cross‐sectional study

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Prevalence of tophus: Q1 6.3% · Q2 19.6% · Q3 33.6% · Q4 36.5%

Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients

2026-11-04T23:43:54.165Z

Secondary analysis · Clin Exp Rheumatol, 2021. Change in Fib-4 score, 6 months: Pegloticase responders 0.13 ± 0.62 · Placebo 0.26 ± 0.41

Predictors of disease activity in gout: a 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Association of tophi with disease activity at T12, 12 months — Tophi vs No tophi: regression coefficient (PASS at T12) -15.3 (95% CI -25.5, -5.2); p=0.003; adjusted for age, sex, disease duration, serum uric acid (sUA) <6 mg/dL, tender joint count, PASS at T0, urate-lowering therapy (ULT)

Sex and country differences in gout: cross-country comparison between Sweden and the UK

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2023. Age at gout onset — Sweden vs UK; p<0.0001

Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review

2026-11-04T23:37:51.551Z

Meta-analysis · J Rheumatol, 2022. Characteristics of patients with colchicine-induced myelosuppression: Renal impairment comorbidity 21/47, 44.7%

The Burden of Gout and Its Attributable Risk Factors in the Middle East and North Africa Region, 1990 to 2019

2026-11-04T23:37:51.551Z

Secondary analysis · J Rheumatol, 2022. Gout burden, MENA region, age-standardized, 2019: Age-standardized point prevalence per 100,000 509.1

Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set

2026-11-04T23:02:07.938Z

Randomized controlled trial · Semin Arthritis Rheum, 2023. Trials reporting all core domains (5 acute; 7 chronic): Acute trials 3 (8%) · Chronic trials 0

Systematic review of colchicine neuromyopathy: Risk factors, duration and resolution

2026-11-04T23:02:07.938Z

Meta-analysis · Semin Arthritis Rheum, 2022. Colchicine neuromyopathy: presentation and risk factors: Features of both neuropathy and myopathy (myopathy symptoms predominant) n=72, 51%

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease

2026-11-04T22:58:59.711Z

Diagnostic or prognostic study · RMD Open, 2023. Diagnostic performance of the DC sign for gout: Static DC sign: sensitivity 58.0% (95% CI 46.5% to 68.9%); specificity 89.3% (95% CI 80.6% to 95.0%); accuracy 73.9% (95% CI 66.5% to 80.5%) · Dynamic DC sign: specificity 97.6% (95% CI 91.7% to 99.7%); accuracy 78.2% (95% CI 71.1% to 84.2%)

TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cells

2026-11-04T22:57:04.788Z

Mechanistic study · Arthritis Res Ther, 2023. TGF-β mRNA elevated in gout patients vs healthy controls

Agreement Among Multiple Observers on Crystal Identification by Synovial Fluid Microscopy

2026-11-04T22:50:06.138Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2022. Interrater agreement (Cohen's kappa): Overall κ (95% CI 0.64-0.84), good agreement 0.74

Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease: A Nationwide Study of Veterans

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. MACE — CPPD vs Non-CPPD: HR 0.98 (95% CI 0.94-1.02); fully adjusted

Changes in Tophus Composition During Urate‐Lowering Therapy: A Dual‐Energy Computed Tomography Study

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Tophus composition change over 2 years, year 2: Mean ± SD total tophus volume, baseline to 2 years (cm3), P < 0.0001 5.17 ± 5.55 to 2.61 ± 2.73

Confirming Prior and Identifying Novel Correlates of Acute Calcium Pyrophosphate Crystal Arthritis

2026-11-04T22:50:06.138Z

Case-control study · Arthritis Care Res (Hoboken), 2022. Correlates of acute CPP crystal arthritis, fully adjusted: OA, OR 3.08

Development and Validation of an Emergency Department Electronic Medical Record Gout Flare Alert

2026-11-04T22:50:06.138Z

Diagnostic or prognostic study · Arthritis Care Res (Hoboken), 2023. Diagnostic properties of the gout flare alert: Gout flare alert: PPV 47% (95% CI 34-60%); NPV 94% (95% CI 90-98%); Sensitivity 75% (95% CI 61-89%); Specificity 82% (95% CI 76-88%)

Familial Risk of Gout and Interaction With Obesity and Alcohol Consumption: A Population‐Based Cohort Study in Korea

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Risk of gout — Family history vs No family history: HR 2.42 (95% CI 2.39, 2.46)

Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long‐Term Urate‐Lowering Therapy in the American College of Rheumatology RISE Registry

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Patients with at least 1 SU recorded 56%

Using Data‐Driven Approaches to Classify and Predict Health Care Spending in Patients With Gout Using Urate‐Lowering Therapy

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Spending trajectory group membership and prediction (boosted C statistic, all predictors), 2 years: Minimal spending 13.2%; C statistic 0.89 · Moderate spending 37.4%; C statistic 0.78 · High spending 49.4%; C statistic 0.90

Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses

2026-11-04T22:45:44.055Z

Diagnostic or prognostic study · Rheumatology (Oxford), 2022. Gout 1.60% · AH 19.59%

Ultrasonography in the prediction of gout flares: a 12-month prospective observational study

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. Baseline US scores and flare occurrence and number (multivariate), 12 months — Total MSU score: aOR (flare occurrence) 1.75 (95% CI 1.26, 2.43)

Upregulated expression of FFAR2 and SOC3 genes is associated with gout

2026-11-04T22:45:44.055Z

Cross-sectional study · Rheumatology (Oxford), 2022. FFAR2 expression (fold changes (FC)): Gout flare 2.9 FC · Inter-critical gout 1.8 FC · Normal SU 1.1 FC · AH 1.1 FC · AH + MSU 1.1 FC

Altered Risk of Incident Gout According to Changes in Metabolic Syndrome Status: A Nationwide, Population‐Based Cohort Study of 1.29 Million Young Men

2026-11-04T22:39:06.224Z

Cohort study · Arthritis Rheumatol, 2023. Incident gout — Chronic metabolic syndrome vs No metabolic syndrome: aHR 3.82 (95% CI 3.67-3.98)

Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia

2026-11-04T22:39:06.224Z

Mechanistic study · Arthritis Rheumatol, 2023. Hyperuricemia-independent mechanisms in normouricemic erosive gout (proband): lubricin level, gene variants, cathepsin G activity, and lubricin/TLR-2 effects in cells and mice: Lubricin level attenuated in proband serum, associated with elevated acute-phase reactants and inflammatory whole-blood transcripts and transcriptional pathways

Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

2026-11-04T22:39:06.224Z

Research article · Arthritis Rheumatol, 2023. Age at gout onset (β in years per unit PRS), men — European men: β -3.61 years per unit PRS (95% CI -4.32, -2.90)

Associations Between Low Serum Urate, Body Composition, and Mortality

2026-11-04T22:39:06.224Z

Cross-sectional study · Arthritis Rheumatol, 2022. Low appendicular lean mass index (ALMI) Z scores (low lean mass): Low serum UA 29% · Normal serum UA 16%

Gout and Excess Risk of Severe SARS–CoV‐2 Infection Among Vaccinated Individuals: A General Population Study

2026-11-04T22:39:06.224Z

Cohort study · Arthritis Rheumatol, 2022. Breakthrough COVID-19 infection (vaccinated cohort): Gout 1,955 (4.68 cases per 1,000 person-months) · Without gout 52,468 (3.76 cases per 1,000 person-months)

Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective Cohorts

2026-11-04T22:39:06.224Z

Cohort study · Arthritis Rheumatol, 2023. Incident gout, healthy vs unhealthy DASH by GRS stratum (all cohorts combined) — Healthy DASH vs Unhealthy DASH: multivariable RR 0.67 (95% CI 0.60-0.76); P for multiplicative interaction = 0.001; among higher GRS

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings

2026-11-04T22:39:06.224Z

Randomized controlled trial · Arthritis Rheumatol, 2022. Treatment response, month 6: MTX 71 (71.0%) · Placebo 20 (38.5%)

Reliability and Diagnostic Accuracy of Radiography for the Diagnosis of Calcium Pyrophosphate Deposition: Performance of the Novel Definitions Developed by an International Multidisciplinary Working Group

2026-11-04T22:39:06.224Z

Diagnostic or prognostic study · Arthritis Rheumatol, 2023. Diagnostic accuracy for CPPD (overall): Radiography: specificity 92%; sensitivity 54%

Association of Healthy Lifestyle Factors and Obesity-Related Diseases in Adults in the UK

2026-11-04T19:13:11.788Z

Cohort study · JAMA Netw Open, 2023. Obesity-related diseases, obesity with 4 vs 0 healthy lifestyle factors — OBESITY, 4 HEALTHY LIFESTYLE FACTORS vs OBESITY, 0 HEALTHY LIFESTYLE FACTORS: HR (hypertension) 0.84 (95% CI 0.78-0.90)

Trends in Prevalence of Gout Among US Asian Adults, 2011-2018

2026-11-04T19:13:11.788Z

Cross-sectional study · JAMA Netw Open, 2023. Age- and sex-adjusted gout prevalence among Asian Americans, 2011 to 2012 vs 2017 to 2018 — Asian vs White: age- and sex-adjusted OR 1.61 (95% CI 1.03-2.51); 2017 to 2018

The frequency of synovitis and calcium pyrophosphate deposition with ultrasound is increased in transfusion-dependent beta-thalassaemia patients: effect of iron accumulation?

2026-11-04T19:02:33.172Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Moderate/severe synovitis on US — TD vs TND: Moderate/severe synovial hypertrophy (SH): 34.8% vs none; p<0.001

Clustering Patients With Gout Based on Comorbidities and Biomarkers: A Cross-Sectional Study

2026-11-04T18:58:37.862Z

Cross-sectional study · J Rheumatol, 2022. Hierarchical cluster analysis identified 3 clusters

Patient-Reported Outcomes in Calcium Pyrophosphate Deposition Disease Compared to Gout and Osteoarthritis

2026-11-04T18:58:37.862Z

Cross-sectional study · J Rheumatol, 2023.

Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study

2026-11-04T18:58:37.862Z

Cohort study · J Rheumatol, 2022. Gout flare prevalence: Gout flare 26 (18%)

Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients

2026-11-04T18:54:43.126Z

Cross-sectional study · RMD Open, 2023. Comorbidities by sex: Obesity, dyslipidaemia, CKD, diabetes mellitus, HF, dementia, urinary tract infection and concurrent rheumatic disease more common in women

Global, regional and national burdens of gout in the young population from 1990 to 2019: a population-based study

2026-11-04T18:54:43.126Z

Cross-sectional study · RMD Open, 2023. Gout burden, ages 15-39 years, 1990–2019: Global gout prevalent cases, 2019 5.21 million

Association of the Quantity, Duration, and Type of Alcohol Consumption on the Development of Gouty Tophi

2026-11-04T18:49:03.987Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2022. Presence of US-detected tophi and subcutaneous tophi (multivariable) — Excessive drinkers vs Non-drinkers: OR 1.79; all P < 0.05; 2.00 after adjustment; >70 gm/week

Canakinumab's Effect Against Subsequent Gout Flares and High‐Sensitivity C‐Reactive Protein Levels: A Causal Mediation Analysis

2026-11-04T18:49:03.987Z

Secondary analysis · Arthritis Care Res (Hoboken), 2022. Gout flare, overall cohort — Canakinumab vs Placebo: HR 0.50 (95% CI 0.37-0.68); Cox regression

Cause‐Specific Mortality in Patients With Gout in the US Veterans Health Administration: A Matched Cohort Study

2026-11-04T18:49:03.987Z

Cohort study · Arthritis Care Res (Hoboken), 2022. All-cause mortality: Gout 246,291; patient-years 4,250,371 · Non-gout controls 2,000,000; patient-years 40,441,353

Imaging Features of Calcium Pyrophosphate Deposition Disease: Consensus Definitions From an International Multidisciplinary Working Group

2026-11-04T18:49:03.987Z

Guideline or statement · Arthritis Care Res (Hoboken), 2022. Consensus definitions of CPPD imaging features (conventional radiography (CR), computed tomography (CT), dual-energy CT (DECT), magnetic resonance imaging (MRI)): Consensus on all CR definitions (Combined Expert Committee survey)

Impact of Clinical Association Between Gout and Dementia: A Nationwide Population‐Based Cohort Study in Korea

2026-11-04T18:49:03.987Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Overall dementia: Gout 81 · Controls 558

Impact of Television Depictions of Gout on Perceptions of Illness: A Randomized Controlled Trial

2026-11-04T18:49:03.987Z

Randomized controlled trial · Arthritis Care Res (Hoboken), 2023. Perceptions of gout, its causes and management

Incident Gout and Risk of First‐Time Acute Coronary Syndrome: A Prospective, Population‐Based Cohort Study in Sweden

2026-11-04T18:49:03.987Z

Cohort study · Arthritis Care Res (Hoboken), 2022. First-time ACS: Gout IR 9.1 of 1,000 person-years · Controls IR 6.3 of 1,000 person-years

Predictors of Patient and Physician Assessments of Gout Control

2026-11-04T18:49:03.987Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2022. Gout control score (NRS 0-10): Patient mean 8.09 ± 2.24 · Physician mean 7.38 ± 2.63

Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate‐Lowering Therapy in Ontario, Canada

2026-11-04T18:49:03.987Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Factors associated with SUA monitoring within 6 months (vs rheumatologists for prescriber specialty) — Family physicians vs Rheumatologists: OR 0.26 (95% CI 0.23-0.29)

In patients with acute mono/oligoarthritis, a targeted ultrasound scanning protocol shows great accuracy for the diagnosis of gout and CPPD

2026-11-04T18:44:40.719Z

Diagnostic or prognostic study · Rheumatology (Oxford), 2022. Diagnostic accuracy for gout: Targeted US protocol: sensitivity 0.91; specificity 0.91; AUC 0.91 · Target joint US: AUC 0.84

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes

2026-11-04T18:44:40.719Z

Cohort study · Rheumatology (Oxford), 2022. New-onset gout: SGLT2I 2.5 (95% CI 2.2, 2.9); Incidence rate 2.5 · DPP4I 5.2 (95% CI 4.8, 5.8); Incidence rate 5.2